The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer

3Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Alternative splicing (AS) analysis across the entire spectrum of human prostate cancer evolution reveals the unexpected findings that intron retention is a hallmark of stemness and tumor aggressiveness, and androgen receptor controls a splicing program distinct from its transcriptional regulation. Importantly, twisted activity of the spliceosome causing abnormal AS landscape represents a therapeutic vulnerability in aggressive prostate cancer. .

Cite

CITATION STYLE

APA

Zou, C., & Zhang, D. (2020, September 2). The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer. Molecular and Cellular Oncology. Taylor and Francis Ltd. https://doi.org/10.1080/23723556.2020.1778420

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free